Skip to main
URGN
URGN logo

UroGen Pharma (URGN) Stock Forecast & Price Target

UroGen Pharma (URGN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 23%
Hold 23%
Sell 0%
Strong Sell 0%

Bulls say

UroGen Pharma Ltd has demonstrated strong financial performance with a projected increase in top-line sales from $114.1 million in 2025 to $338.8 million by 2026, reflecting robust growth in the company's revenue streams. The company reported a 9% year-over-year growth in net product revenue, achieving $90.4 million in full-year 2024, while Jelmyto revenue in Q4 2024 rose to $24.6 million, indicating a 15% increase in underlying demand. Furthermore, favorable clinical results from the Phase 3 ENVISION trial for UGN-102 indicate a substantial market opportunity exceeding $5 billion, positioning UroGen for potential transformative impact in the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.

Bears say

UroGen Pharma Ltd reported a significant full-year net loss of $126.9 million, translating to a loss of $2.96 per share, with a further projected net loss of $3.01 per diluted share, indicating ongoing financial challenges. Key risks contributing to a negative outlook include potential market penetration issues due to increased competition, potential failures in clinical trials, and the inability to secure market exclusivity for critical products, such as UGN-103 and UGN-104. Although the company recorded $24.6 million in fourth-quarter revenue, it represented a modest miss against expectations, while net losses in Q4 widened to $37.5 million compared to $26 million in the previous year, underscoring concerns about its long-term financial viability.

UroGen Pharma (URGN) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 23% recommend Buy, 23% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About UroGen Pharma (URGN) Forecast

Analysts have given UroGen Pharma (URGN) a Buy based on their latest research and market trends.

According to 13 analysts, UroGen Pharma (URGN) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

UroGen Pharma (URGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.